MEK-2 Polyclonal Antibody

    • Catalog No.:YT2716
    • Applications:WB,IHC-p,IF(paraffin section),IP,ELISA
    • Reactivity:Human,Mouse,Rat
      • Gene Name:
      • MAP2K2
      • Protein Name:
      • Dual specificity mitogen-activated protein kinase kinase 2
      • Human Gene Id:
      • 5605
      • Human Swiss Prot No:
      • P36507
      • Mouse Swiss Prot No:
      • Q63932
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human MAP2K2. AA range:261-310
      • Specificity:
      • MEK-2 Polyclonal Antibody detects endogenous levels of MEK-2 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Rabbit
      • Dilution:
      • Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunoprecipitation: 2-5 ug/mg lysate. ELISA: 1/10000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -20°C/1 year
      • Other Name:
      • MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein kinase kinase 2; MAP kinase kinase 2; MAPKK 2; ERK activator kinase 2; MAPK/ERK kinase 2; MEK 2
      • MolecularWeight(Da):
      • 44424
      • Observed Band(KD):
      • 44
      • Background:
      • mitogen-activated protein kinase kinase 2(MAP2K2) Homo sapiens The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008],
      • Function:
      • catalytic activity:ATP + a protein = ADP + a phosphoprotein.,disease:Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.,function:C
      • Subcellular Location:
      • extracellular region,nucleus,cytoplasm,mitochondrion,early endosome,late endosome,peroxisomal membrane,endoplasmic reticulum,Golgi apparatus,cytosol,microtubule,cell-cell junction,focal adhesio
      • Expression:
      • Colon carcinoma,Epithelium,Human cerebellum,Muscle,Platelet
      • Products Images
      • Western blot analysis of mouse-lung KB 293T lysis using MEK-2 antibody. Antibody was diluted at 1:2000
      • Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using MEK2 Antibody. The picture on the right is blocked with the synthesized peptide.
      • Western blot analysis of lysates from ovary cancer cells, using MEK2 Antibody. The lane on the right is blocked with the synthesized peptide.